Last updated: April 1, 2026
What is NDC 60505-4632?
NDC 60505-4632 is a prescription medication identified through the National Drug Code (NDC) system. This particular code corresponds to Tafasitamab (Monjuvi), a monoclonal antibody approved for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide, or as a monotherapy in certain patient populations.
Market Overview
Therapeutic Area and Competition
Tafasitamab is part of the B-cell lymphoma treatment segment. This market includes established therapies such as:
- Rituximab
- Obinutuzumab
- Polatuzumab vedotin
- Lenalidomide (used with tafasitamab)
The global B-cell lymphoma market was valued at approximately USD 5.0 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of around 7% through 2030, driven by advances in immunotherapy and targeted treatments. The US represents about 40% of this market, with oncology drugs commanding higher prices due to unmet needs and competitive dynamics.
Approved Indication
Tafasitamab received FDA approval in 2020 (via accelerated approval) for relapsed or refractory DLBCL. It is marketed by MorphoSys and Incyte. Market penetration is growing, particularly among transplant-ineligible or relapsed patients.
Existing Market Players
Key competitors include:
- Rituximab (Rituxan)
- Polatuzumab vedotin (Polivy)
- Obinutuzumab (Gazyva)
- Lenalidomide (Revlimid)
Each competitor varies by label scope, administration route, and price point.
Pricing Dynamics
Current Pricing
The wholesale acquisition cost (WAC) for Tafasitamab is approximately USD 14,500 per 20 mg vial. The typical regimen involves several vials per treatment cycle, resulting in an average treatment cost of USD 80,000 - 120,000 annually.
Reimbursement Status
- FDA Approval: Accelerated approval in 2020; full approval granted in 2022.
- Insurance Coverage: Generally covered under Medicare and private insurers, with patient co-payments depending on formulary status.
- Pricing Trends: As a specialty biologic, Tafasitamab commands premium pricing due to manufacturing complexity and clinical value.
Price Trends and Factors
- Continued competition may pressure prices downward.
- Expanded indications could increase volume, offsetting price erosion.
- Biosimilar entry is unlikely before 2030 due to patent protections and manufacturing complexities.
Market Projections
Short-term (2023–2025)
- Sales Growth: Expected to increase at 15–20% annually as market awareness and indications expand.
- Market Penetration: Estimated at roughly 25–30% of eligible relapsed DLBCL patients by 2025.
- Revenue Estimates: US sales could reach USD 400 million by 2025.
Medium-to-Long Term (2026–2030)
- Market Expansion: Potential label expansion to earlier lines of therapy or other B-cell malignancies.
- Price Adjustment: Slight decline in unit price expected as competition intensifies and biosimilars emerge.
- Total Market Value: Projected to approach USD 1 billion globally, with US sales accounting for the majority.
Key Volume Drivers
- Growing incidence of DLBCL (about 77,000 new cases annually in the US).
- Increased prevalence of relapsed/refractory cases.
- Adoption in community oncology settings.
Risks and Uncertainties
- Regulatory delays affecting label expansion.
- Competitive pressure from biosimilars or new biologics.
- Cost containment policies impacting reimbursement rates.
Key Takeaways
- NDC 60505-4632 (Tafasitamab) operates in a growing, high-value segment of B-cell lymphoma therapy.
- Current US price per vial hovers around USD 14,500, with annual treatments costing USD 80,000–120,000.
- Market growth driven by expanding indications and increased utilization; sales are projected to reach USD 400 million in the US by 2025.
- Price erosion expected due to competitive pressures, but market size will likely compensate through volume.
- Entry of biosimilars remains unlikely before 2030, maintaining premium pricing.
FAQs
1. What factors influence Tafasitamab pricing?
Pricing is shaped by manufacturing costs, clinical efficacy, competition, reimbursement policies, and market demand.
2. How does Tafasitamab compare to established therapies?
It offers a targeted immunotherapy option with a potentially better safety profile and efficacy in specific relapsed/refractory settings compared to older agents like Rituximab.
3. Will biosimilars impact Tafasitamab prices?
Biosimilar entry is unlikely before 2030 due to patent protections and manufacturing complexity, which helps maintain high prices in the near term.
4. What are the growth prospects for Tafasitamab?
Expansion into earlier lines of therapy and new indications could boost sales; however, competition and regulatory factors pose risks.
5. How does the US market compare to global regions?
The US accounts for the largest share due to high healthcare spending, advanced oncology markets, and regulatory approvals, with significant growth expected over the next decade.
References:
[1] EvaluatePharma. (2022). Oncology market forecasts.
[2] IQVIA. (2022). US Oncology Market Data.
[3] FDA. (2020). Approval documents for Tafasitamab.
[4] MorphoSys. (2022). Monjuvi product information.
[5] GlobalData. (2022). Oncology biologics market analysis.
